(Press-News.org) DANVERS, Mass., May 18, 2023 – Abiomed, part of Johnson & Johnson MedTech[1], announces results of a third-party analysis showing that utilizing Impella during high-risk percutaneous coronary intervention (PCI) procedures may help physicians achieve a more complete revascularization compared to high-risk PCIs supported using an intra-aortic balloon pump (IABP). Previous studies have shown that a more complete revascularization can lead to longer survival[2],[3], a greater reduction in heart failure and angina symptoms[4], and an improved quality of life for the patient[5].
This analysis shows more patients achieved a more complete revascularization with Impella than with IABP support during high-risk PCIs (see Figure 1; p for categorical allocation <0.001). Vasileios Panoulas[6], MD, FRCP, PhD, FESC, consultant interventional cardiologist, Royal Brompton and Harefield hospitals, presented this data today during EuroPCR 2023, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in Paris, France, which is taking place between May 16-19, 2023.
The PROTECT II Randomized Controlled Trial (RCT), PROTECT III and RESTORE-EF prospective studies were included in this analysis and individual patient data were pooled between these three studies. Coronary artery disease severity was measured pre-PCI using SYNTAX score[7] and post-PCI using residual SYNTAX Score (rSS)[8]. The analysis compared complete revascularization rates, as measured by rSS< 2, between high-risk PCI patients who received Impella support (N=880) and IABP support (N=155).
Results of a multiple regression analysis showed a 40% greater reduction of residual SYNTAX Score post-PCI in patients treated with Impella compared to IABP (95% CI 27-50%, p<0.001). Defining complete revascularization (CR) as rSS< 2, CR was achieved in 42.2% of Impella patients vs. 20.6% of IABP patients. “When taking study limitations into account, this pooled analysis showcases the potential of Impella to contribute to improved long-term patient outcomes by allowing a greater extent and quality of revascularization,” said Panoulas.
Previous studies have shown that a more complete revascularization is associated with longer patient survival and patients with residual SYNTAX Score >8 were associated with 37% all-cause mortality at five years against 9% for rSS=0 (HR=5.12, 95% CI 3.32-7.90, P<0.001)[9]. In other meta-analyses, rSS=0 was associated with 29% lower all-cause mortality (p=0.001) and 25% fewer major adverse events (p<0.001)[10].
This analysis supports the hypotheses incorporated in the ongoing PROTECT IV RCT. PROTECT IV is an on-label, prospective, multi-center RCT designed to provide the level of clinical evidence needed to achieve a global Class I guideline recommendation for Impella in high-risk PCI in the future.
The pooled data analysis was led by the York Health Economics Consortium (YHEC), an independent research company owned by the University of York (England).
About Abiomed
Based in Danvers, Massachusetts, USA, Abiomed, part of Johnson & Johnson MedTech, is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit www.abiomed.com.
About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding Impella 2.5, Impella CP and Impella CP with SmartAssist. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Abiomed, Inc., any of the other Johnson & Johnson MedTech Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Abiomed, Inc., the Johnson & Johnson MedTech Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
For further information please contact:
Jenny Leary
Associate Director, US Communications
jleary@abiomed.com
978-882-8491
[1] Abiomed, Inc. is part of Johnson & Johnson MedTech, which comprises the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson's MedTech segment.
[2] Garcia S, Sandoval Y, Roukoz H, et al. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. J Am Coll Cardiol 2013;62:1421-31.
[3] Nagaraja V, Ooi SY, Nolan J, et al. Impact of Incomplete Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2016;5.
[4] National Institute of Health and Care Excellence. Stable Angina: Management. Clinical Guideline [CG126]. NICE, 2011. Available from https://www.nice.org.uk/guidance/cg126/chapter/Guidance#investigation-and-revascularisation. Accessed on May 12, 2023.
[5] Mehta SR, Wang J, Wood DA, et al. Complete Revascularization vs Culprit Lesion-Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Randomized Clinical Trial. JAMA Cardiol 2022;7:1091-1099.
[6] Dr. Panoulas has received consulting fees and honoraria from Abiomed, Inc.
[7] Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005;1:219-27.
[8] Genereux P, Palmerini T, Caixeta A, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. J Am Coll Cardiol 2012;59:2165-74.
[9] Farooq V et al. Quantification of incomplete revascularization and its association with 5-year mortality in the SYNTAX trial validation of the residual SYNTAX score. Circulation 2013;128:141-51.
[10] Ahn JM et al. Comparison of Stenting Versus Bypass Surgery According to the Completeness of Revascularization in Severe Coronary Artery Disease: Patient-Level Pooled Analysis of the SYNTAX, PRECOMBAT, and BEST Trials. JACC Cardiovasc Interv 2017;10:1415-1424.
END
Analysis showcases potential for more complete revascularizations with Impella compared to IABP during HRPCI
2023-05-18
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Novel high-efficiency assay promises rapid mitochondrial disease diagnosis
2023-05-18
The gene ECHS1 encodes for enoyl-CoA hydratase short-chain 1, a mitochondrial enzyme involved in branched-chain amino acid and fatty acid metabolism. Rare inherited mutations in the ECHS1 lead to mitochondrial ECHS1 deficiency, resulting in the disruption of the metabolism of the essential amino acid valine and accumulation of valine intermediates.
In fact, ECHS1 is one of the most common causative genes of mitochondrial diseases. These mutant enzymes also cause brain lesions and severe delays in a child’s psychomotor development, along with elevating blood lactate levels. ECHS1 variants have been reported globally, and many disease-causing ...
A new tool for deforestation detection
2023-05-18
Every second, the planet loses a stretch of forest equivalent to a football field due to
logging, fires, insect infestation, disease, wind, drought, and other factors. In a recently published study, researchers from the U.S. Geological Survey Earth Resources Observation and Science (EROS) Center presented a comprehensive strategy to detect when and where forest disturbance happens at a large scale and provide a deeper understanding of forest change.
The study was published on Feb. 28 in the Journal of Remote Sensing.
“Our strategy leads to more accurate land cover ...
To avoid a battery crisis, more of us should share small, lightweight EVs
2023-05-18
Most global scenarios and governmental targets for decarbonizing the transport sector consider battery-powered electric vehicles as a main part of the solution. Enormous amounts of raw materials are needed to build enough batteries and ensure a transition to low-emission vehicles.
Access to lithium is critical, as it is used in all types of EV batteries.
Future demand needs to decrease
“It seems very likely we'll have a shortage. The key lies in the demand. The demand needs to decrease to avoid long-term supply problems,” ...
Space missions set to improve solar storm forecasts
2023-05-18
Satellites launched into outer space could send back improved warnings of dangerous solar storms thanks to a breakthrough in the way scientists use space weather measurements.
Experts from the University of Reading have found that using satellite data that is less reliable but is returned to Earth rapidly can be used to improve the accuracy of solar wind forecasts - which are harmful streams of charged particles sent from the sun - by nearly 50 per cent.
Their research, published today (Thursday, 18 May) in Space Weather, ...
Perfect ‘pathogen’ storm: Vibrio bacteria, Sargassum and plastic marine debris
2023-05-18
A new study uncovers how the interplay between Sargassum spp., plastic marine debris and Vibrio bacteria creates the perfect “pathogen” storm that has implications for both marine life and public health. Vibrio bacteria are found in waters around the world and are the dominant cause of death in humans from the marine environment. For example, Vibrio vulnificus, sometimes referred to as flesh-eating bacteria, can cause life-threatening foodborne illnesses from seafood consumption as well as disease and death from open wound infections.
Since 2011, ...
The importance of social media in corporate social responsibility
2023-05-18
A new study by Dr. Lucie Kvasničková Stanislavská from Czech University of Life Sciences, Prague published in PeerJ Computer Science titled ‘Global analysis of Twitter communication in corporate social responsibility area: sustainability, climate change, and waste management’ has found that social media is an increasingly important tool for companies to communicate their corporate social responsibility (CSR) efforts. The study analyzed over half a million tweets from 2017 to 2022 and identified the key topics and trends communicated in connection with CSR on Twitter.
“Our results aid enterprises in developing communication ...
SCAI releases guidance on management of in-stent restenosis and stent thrombosis
2023-05-18
PHOENIX (May 18, 2023) – The Society for Cardiovascular Angiography & Interventions (SCAI) today release an expert consensus on the management of in-stent restenosis and stent thrombosis. The statement was published online in the Journal of the Society for Cardiovascular Angiography &
Interventions (JSCAI).
In-stent restenosis is a blockage or narrowing that comes back in the portion of the coronary artery previously treated with a stent and remains a common clinical problem despite numerous improvements in stent design and polymer coatings in recent years. In addition to significant health care
costs, it is also associated with an increased risk of death and re-hospitalization. ...
Past climate change to blame for Antarctica’s giant underwater landslides
2023-05-18
Scientists have discovered the cause of giant underwater landslides in Antarctica which they believe could have generated tsunami waves that stretched across the Southern Ocean.
An international team of researchers has uncovered layers of weak, fossilised and biologically-rich sediments hundreds of metres beneath the seafloor.
These formed beneath extensive areas of underwater landslides, many of which cut more than 100metres into the seabed.
Writing in Nature Communications, the scientists say these weak layers – made up of historic biological material – made the area ...
Time of day may determine the amount of fat burned by cold exposure
2023-05-18
Short-term exposure to cold temperatures activates brown fat that burns calories and has become an attractive target to promote cardiometabolic health. Now new research being presented at this year’s European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May) suggests that this biological response differs depending on the time of day and in men and women.
The preliminary study by Dr Mariëtte Boon from Leiden University Medical Center in the Netherlands and colleagues, suggests that cold exposure in ...
Nearly half of adolescents using semaglutide in trial dropped below the clinical cut-off for obesity
2023-05-18
DUBLIN—A new secondary analysis of the STEP TEENS trial presented at this year’s European Congress on Obesity (ECO 2023, Dublin 17-20 May) and published in the journal Obesity shows that almost half (45%) of the adolescents assigned to semaglutide in the trial managed to lose enough weight to drop below the clinical cutoff for obesity.
The study, led by Aaron S. Kelly, PhD, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota, Minneapolis, and colleagues, also showed almost three quarters (74%) moved down by at least one weight category.
The full STEP TEENS trial, published in 2022 in the New England Journal ...